Attentin® in Children and Adolescents With ADHD - A Non-interventional Study
Launched by MEDICE ARZNEIMITTEL PÜTTER GMBH & CO KG · Jun 13, 2016
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 6 to 17.11 years
- • Current MPH therapy insufficient
- • ADHD was classified according to a validated classification system (e.g. DSM or ICD-10)
- • No contraindication against dexamfetamine
- Exclusion Criteria:
- • Contraindication against dexamfetamine
About Medice Arzneimittel Pütter Gmbh & Co Kg
Medice Arzneimittel Pütter GmbH & Co. KG is a distinguished pharmaceutical company based in Germany, renowned for its commitment to developing innovative therapeutic solutions in the field of healthcare. With a strong focus on neurology, psychiatry, and chronic diseases, Medice leverages advanced research and development methodologies to enhance patient outcomes. The company emphasizes rigorous clinical trials and regulatory compliance, ensuring the safety and efficacy of its products. Medice's dedication to quality, patient-centric solutions, and collaborative partnerships underscores its position as a trusted leader in the pharmaceutical industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mainz, , Germany
Patients applied
Trial Officials
Michael Huss, Prof. Dr.
Principal Investigator
Child and Adolescent Psychiatry, University of Medicine, Mainz, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials